Cartesian Therapeutics Inc. (RNAC) is a Healthcare · Biotechnology company listed on NASDAQ. Price $7.94 (+1.02%), Market cap $0.22B, 52-week low–high $5.85 ~ $13.77.
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, which is in phase 1 trials, an autologous autologous B cell maturation antigen (BCMA) directed mRNA CAR-
Financial statements, price targets, institutional (13F) holdings and related news for Cartesian Therapeutics Inc. are updated in real time on BlackAll Trade.
Cartesian Therapeutics Inc. trades at $7.94 (+1.02%). Real-time quotes and charts are available on BlackAll Trade.
Cartesian Therapeutics Inc. has a market cap of about $0.22B.
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an au